Neumirna Therapeutics, a pioneering biotech company at the forefront of RNA medicine, is thrilled to announce the receipt of its third Innobooster grant from the Innovation Fund Denmark (IFD), totaling 5 million DKK. This substantial funding will be allocated to advance NEUmiRNA's groundbreaking disease-modifying therapy for epilepsy to the clinic, bringing hope to the circa 50 million patients affected by epilepsy worldwide.
Neumirna's CEO, Prof. Janine Erler, expressed excitement about the project’s potential impact, stating:
"Our unprecedented therapy holds the potential to transform the lives of epilepsy patients. With the support from the Innovation Fund Denmark, we plan to take our unique therapy through clinical development, addressing the critical needs of drug-resistant epilepsy patients."
The key element of this project involves the advancement of our preclinical lead candidate NMT.001, specifically designed to target microRNA-134 (miR-134). Our preclinical studies have demonstrated the first evidence of the curative potential of NMT.001 in an NIH-validated model of drug-resistant epilepsy.
As part of the Innobooster-project, Neumirna Therapeutics will conduct Investigational New Drug (IND)-enabling studies to pave the way to the first human clinical trials.
Receiving our third Innobooster grant is a testament to NEUmiRNA’s excellent scientific and commercial potential, and to IFD’s support in our mission to advance innovative therapies addressing critical unmet medical needs.
For media inquiries, please contact:
Prof. Janine Erler, CEO
je@neumirna.com
